224 related articles for article (PubMed ID: 31244107)
1. Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
Li Z; Su K; Jiang Z; Yu Y; You Q; Zhang X
J Med Chem; 2019 Aug; 62(16):7583-7588. PubMed ID: 31244107
[TBL] [Abstract][Full Text] [Related]
2. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
3. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
[TBL] [Abstract][Full Text] [Related]
4. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
[TBL] [Abstract][Full Text] [Related]
5. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
6. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
7. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2022 Aug; 238():114479. PubMed ID: 35675755
[TBL] [Abstract][Full Text] [Related]
9. Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor.
Arsenault PR; Song D; Bergkamp M; Ravaschiere AM; Navalsky BE; Lieberman PM; Lee FS
Chembiochem; 2016 Dec; 17(24):2316-2323. PubMed ID: 27770548
[TBL] [Abstract][Full Text] [Related]
10. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues.
Hong YR; Kim HT; Lee SC; Ro S; Cho JM; Kim IS; Jung YH
Bioorg Med Chem Lett; 2013 Nov; 23(21):5953-7. PubMed ID: 24042008
[TBL] [Abstract][Full Text] [Related]
11. Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor.
Wang RX; Henen MA; Lee JS; Vögeli B; Colgan SP
Gut Microbes; 2021; 13(1):1938380. PubMed ID: 34190032
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of CYP1A2, CYP2B6, and CYP3A4 in Human Hepatocytes by Prolyl Hydroxylase Domain 2 Inhibitors via Hypoxia-Inducible Factor-
Takano H; Yamaguchi JI; Kato S; Hamada M; Tada M; Endo H
Drug Metab Dispos; 2021 Jan; 49(1):20-30. PubMed ID: 33087449
[TBL] [Abstract][Full Text] [Related]
13. The novel prolyl hydroxylase-2 inhibitor caffeic acid upregulates hypoxia inducible factor and protects against hypoxia.
Guo Z; Yang Y; Li L; Zhao Q; Li Y; Liu Z; Hao L; Guo B; Diao A
Eur J Pharmacol; 2022 Nov; 934():175307. PubMed ID: 36191632
[TBL] [Abstract][Full Text] [Related]
14. ExActa HIF prolyl hydroxylase inhibitors-The new lifestyle drug?
Sciesielski LK; Kirschner KM
Acta Physiol (Oxf); 2019 Nov; 227(3):e13370. PubMed ID: 31465609
[No Abstract] [Full Text] [Related]
15. Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy.
Yu Z; Li Z; Yu Q; Wang Z; Song H; Sun H; Fan R; Bi A; Zhang J; Zhang X
Chem Biol Drug Des; 2020 Feb; 95(2):270-278. PubMed ID: 31628888
[TBL] [Abstract][Full Text] [Related]
16. Substrate preference of the HIF-prolyl hydroxylase-2 (PHD2) and substrate-induced conformational change.
Pektas S; Knapp MJ
J Inorg Biochem; 2013 Sep; 126():55-60. PubMed ID: 23787140
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
Kim SY; Yang EG
Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
Holt-Martyn JP; Chowdhury R; Tumber A; Yeh TL; Abboud MI; Lippl K; Lohans CT; Langley GW; Figg W; McDonough MA; Pugh CW; Ratcliffe PJ; Schofield CJ
ChemMedChem; 2020 Feb; 15(3):270-273. PubMed ID: 31751494
[TBL] [Abstract][Full Text] [Related]
19. Nonhypoxic pharmacological stabilization of Hypoxia Inducible Factor 1α: Effects on dopaminergic differentiation of human neural stem cells.
Hey SM; Jensen P; Ryding M; Martínez Serrano A; Kristensen BW; Meyer M
Eur J Neurosci; 2019 Feb; 49(4):497-509. PubMed ID: 30471165
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of the hypoxia-inducible factor prolyl hydroxylase PHD3 by Zn(II).
Na YR; Woo DJ; Choo H; Chung HS; Yang EG
Chem Commun (Camb); 2015 Jul; 51(53):10730-3. PubMed ID: 26051901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
